Positive Phase 1 Data - Phase 2 Trial For MediGene`s Novel Anticancer Therapeutic Being Prepared
(PR Newswire)The biopharmaceutical company MediGene AG announced today that its wholly owned subsidiary MediGene, Inc. based in San Diego, USA, has submitted a final study report of its phase 1 clinical trial for G207, a novel anticancer therapeutic for the treatment of brain tumors to the FDA, the US American Food and Drug Administration.- Mar 06 7:03 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010306/lntu010.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines